The Company

SaNOtize is a global, clinical-stage pharmaceutical company based in Vancouver, Canada. Its patented technologies deliver the natural antimicrobial properties of nitric oxide (NO) to treat a wide range of common viral, bacterial, and fungal infections.

SaNOtize was co-founded in 2017 by Gilly Regev, PhD, a biochemist by training, and Chris Miller, PhD, a longtime leader in the NO field. Together the team pioneered a novel delivery system for NO, enabling it to be used for the first time as a topical antimicrobial.

The company’s lead therapy is a NO-based nasal spray, NONS™, shown to be effective against viruses including COVID-19 and registered or approved in more than 10 countries worldwide. Its groundbreaking approval in India marked the first-ever regulatory drug approval of NO to treat an infection. Other pipeline products include treatments for chronic sinusitis, diabetic foot ulcers, and warts.

In just a few short years, SaNOtize has grown to a staff of over 20, along with a Board of Directors and a Scientific Advisory Board of recognized global experts. The company’s clinical studies on NONS have been published in peer-review journals, and clinical trials for additional applications are underway.


SaNOtize believes that NO has the potential to save lives and improve the quality of life for hundreds of millions of people. The company’s mission is to provide accessible antimicrobial solutions for people suffering from upper respiratory and common topical infections around the world.